BioAge Labs (BIOA) announced that the first participant has been dosed in a Phase 1 clinical trial evaluating BGE-102, a structurally novel, ...

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development ...